{"title":"Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma.","authors":"Lin Zhong, Anqing Lu, Xiyue Lu, Xiaoyin Liu, Lujia Cao, Shihong Zhu, SiJun Diao, Xu Cheng, Hongwei Wu, Jing Chen","doi":"10.1177/15330338251319394","DOIUrl":"10.1177/15330338251319394","url":null,"abstract":"<p><p>Primary central nervous system lymphoma (PCNSL) is a very rare extranodal non-Hodgkin's lymphoma confined to the brain, eyes, spinal cord, and cerebrospinal fluid (CSF). This disease is highly aggressive. For decades, high-dose methotrexate-based induction regimens have been the standard treatment for PCNSL and have significantly improved patient overall survival (OS). However, some patients still experience disease recurrence or develop drug resistance. With a deeper understanding of the pathophysiology of PCNSL, various therapies, including CD20 monoclonal antibodies, Bruton's tyrosine kinase (BTK) inhibitors, immunomodulatory drugs, immune checkpoint inhibitors, phosphoinositide 3-kinase (PI3 K)/mammalian target of rapamycin(mTOR) inhibitors, and chimeric antigen receptor (CAR) -T cells are increasingly being applied and have demonstrated considerable efficacy. These therapies have paved the way for novel treatment strategies in PCNSL, representing a highly promising field. Investigating the mechanisms, specific targets, and signaling pathways, as well as interactions with the tumor microenvironment (TME), can provide a solid foundation for further exploration and potentially enhance the optimization of treatment approaches for PCNSL. This review seeks to explore the characteristics of the TME in PCNSL, elucidate the molecular mechanisms of various immunotherapies and targeted therapies, examine their interactions with the TME, and summarize the advancements in the research of PCNSL immunotherapy and targeted therapy.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251319394"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11800258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrea Gaetano Allegra, Luca Nicosia, Michele Rigo, Nicola Bianchi, Riccardo Filippo Borgese, Antonio De Simone, Niccolò Giaj-Levra, Davide Gurrera, Stefania Naccarato, Edoardo Pastorello, Francesco Ricchetti, Gianluisa Sicignano, Ruggero Ruggieri, Filippo Alongi
{"title":"MR-Guided Adaptive Radiotherapy in Localized Prostate Cancer.","authors":"Andrea Gaetano Allegra, Luca Nicosia, Michele Rigo, Nicola Bianchi, Riccardo Filippo Borgese, Antonio De Simone, Niccolò Giaj-Levra, Davide Gurrera, Stefania Naccarato, Edoardo Pastorello, Francesco Ricchetti, Gianluisa Sicignano, Ruggero Ruggieri, Filippo Alongi","doi":"10.1177/15330338241297231","DOIUrl":"10.1177/15330338241297231","url":null,"abstract":"<p><p>MR-guided radiotherapy (MRgRT) is novel treatment modality in Radiation Oncology that could allow a higher precision and tolerability of Radiation Treatments. This modality is possible due to dedicated systems consisting of a MR scanner mounted on a conventional linac and software that permit daily online treatment plan adaptation. Prostate cancer (PC) is one of the most common malignancies in RO clinical practice and currently under investigation with this new technology. The focus of this review is to describe the current state of the art and clinical results of MRgRT in the treatment of PC. The available technology are briefly described, as well as the published literature and possible future applications.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241297231"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Farshid Mahmoudi, Nahid Chegeni, Ali Bagheri, Amir Danyaei, Samira Razzaghi, Shole Arvandi, Amal Saki Malehi, Bahare Arjmand, Azin Shamsi, Majid Mohiuddin
{"title":"Optimization of the Dose-Volume Effect Parameter \"a\" in EUD-Based TCP Models for Breast Cancer Radiotherapy.","authors":"Farshid Mahmoudi, Nahid Chegeni, Ali Bagheri, Amir Danyaei, Samira Razzaghi, Shole Arvandi, Amal Saki Malehi, Bahare Arjmand, Azin Shamsi, Majid Mohiuddin","doi":"10.1177/15330338251329103","DOIUrl":"10.1177/15330338251329103","url":null,"abstract":"<p><p>IntroductionRadiotherapy treatment plans traditionally rely on physical indices like Dose-volume histograms and spatial dose distributions. While these metrics assess dose delivery, they lack consideration for the biological effects on tumors and healthy tissues. To address this, radiobiological models like tumor control probability (TCP) and Normal tissue complications probability (NTCP) are increasingly incorporated to evaluate treatment efficacy and potential complications. This study aimed to assess the predictive power of radiobiological models for TCP in breast cancer radiotherapy and provide insights into the model selection and parameter optimization.MethodsIn this retrospective observational study, two commonly used models, the Linear-Poisson and Equivalent uniform dose (EUD)-based models, were employed to calculate TCP for 30 patients. Different radiobiological parameter sets were investigated, including established sets from literature (G<sub>1</sub> and G<sub>2</sub>) and set with an optimized \"a\" parameter derived from clinical trial data (a<sub>1</sub> and a<sub>2</sub>). Model predictions were compared with clinical outcomes from the START trials.ResultsThe Linear-Poisson model with es lished parameter sets from the literature demonstrated good agreement with clinical data. The standard EUD-based model (a = -7.2) significantly underestimated TCP. While both models exhibited some level of independence from the specific parameter sets (G<sub>1</sub> vs. G<sub>2</sub>), the EUD-based model was susceptible to the \"a\" parameter value. Optimization suggests a more accurate \"a\" value closer to -2.57 and -5.65.ConclusionThis study emphasizes the importance of clinically relevant radiobiological parameters for accurate TCP prediction and optimizing the \"a\" parameter in the EUD-based model based on clinical data (a1 and a2) improved its predictive accuracy significantly.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251329103"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143754603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Li-Xin Li, Yun Hao, Lei Dong, Zhong-Qi Qiao, Shun-Chao Yang, Yan-Duo Chen, Kai Zhang, Ya-Wen Wang
{"title":"Circular RNAs as Biomarkers in Breast Cancer Diagnosis, Prognosis, Molecular Types, Metastasis and Drug Resistance.","authors":"Li-Xin Li, Yun Hao, Lei Dong, Zhong-Qi Qiao, Shun-Chao Yang, Yan-Duo Chen, Kai Zhang, Ya-Wen Wang","doi":"10.1177/15330338251328500","DOIUrl":"10.1177/15330338251328500","url":null,"abstract":"<p><p>Breast cancer is one of the leading causes of cancer-related deaths in women worldwide. Circular RNAs (circRNAs), a novel class of endogenous noncoding RNA with a covalently closed continuous loop that lacks the 5'-cap structure and the 3'-poly A tail, are more stable than linear RNAs and less susceptible to degradation by nucleases. CircRNAs are widespread in multiple mammalian genomes and have been detected in various tissues, cells and body fluids. Increasing evidence shows that abnormal expression of circRNAs is involved in the development of a variety of diseases, including breast cancer. Numerous studies have explored the potential of circRNAs as biomarkers in various malignant tumors. In this review, we aim to provide a comprehensive overview of the latest advances in circRNAs as promising biomarkers in the early diagnosis, prognosis, molecular type, metastasis and drug resistance of breast cancer.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251328500"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Role of 3D Printing and Augmented Reality in the Management of Hepatic Malignancies.","authors":"Filippos F Karageorgos, Ion-Anastasios Karolos, Theodoros Pettas, Vassilios Tsioukas, Christos Pikridas, Georgios Tsoulfas","doi":"10.1177/15330338251323138","DOIUrl":"10.1177/15330338251323138","url":null,"abstract":"<p><p><b>Introduction:</b> 3-dimensional (3D) printing and augmented reality (AR) are emerging technologies that are used in a wide variety of scientific fields. Among them, medicine is one of the most promising fields of application since these technologies can benefit not only surgeons, but also medical/surgical trainees, patients and can potentially benefit health care systems with better educated staff working on personalized solutions for the patients. Thus, potentially reducing intra-operative and post operative complications and overall costs for the health care systems. Hepatic malignancy surgeries are some of the most demanding surgeries that could a general surgeon perform. The intra-operative and post-operative risks and complications render them demanding. In literature there are cases of research studies including applications of 3D printing and augmented reality in hepatic malignancies. <b>Methods:</b> For this, a comprehensive literature search was conducted on Scopus and Pubmed databases (latest search September 5, 2024). Research studies that included applications of 3D printing and AR in hepatic malignancies were eligible for the review. <b>Results:</b> Herein, twelve papers have been included and presented, which either include the use of 3D printing or the use of AR. There are some cases where both technologies were used simultaneously. 3D printing technology and AR can be used alone or in combination together to aid in the management of hepatic malignancies. <b>Conclusion:</b> Encouraging results (eg, efforts to reduce cost of 3D printing, proper surgical pre-planning, usefulness in education of medical personnel and patients) from the use of these technologies, not only qualitatively but also quantitatively, show that the medical staff can help patients and improve their part of the health system. Yet much more studies need to validate whether the use of these two technologies provides positive results on the surgeries or not.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251323138"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rami Yanes, Turcin Saridogan, Vikram Gorantla, Abigail Overacre, Ronan W Hsieh, James Celebrezze, Tara Magge, Meghana Singhi, Anwaar Saeed, Amer H Zureikat, Arvind N Dasari, Ibrahim Halil Sahin
{"title":"Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer.","authors":"Rami Yanes, Turcin Saridogan, Vikram Gorantla, Abigail Overacre, Ronan W Hsieh, James Celebrezze, Tara Magge, Meghana Singhi, Anwaar Saeed, Amer H Zureikat, Arvind N Dasari, Ibrahim Halil Sahin","doi":"10.1177/15330338251317094","DOIUrl":"10.1177/15330338251317094","url":null,"abstract":"<p><p>The management of early-stage colon cancer involves surgical resection of the primary tumor with or without chemotherapy, depending on pathological staging. The benefit of adjuvant chemotherapy for stage II and III colon cancer is approximately 5% and 15%, indicating the need for optimization for risk stratification and patient selection. Several studies have revealed that current clinicopathological factors lack precision. Circulating tumor DNA (ctDNA) is cell-free DNA originating from cancer cells and can be detected even in the absence of radiologically detectable disease among patients with colon cancer. Recent cohort studies revealed that ctDNA is one of the most significant prognostic factors for patients with early-stage colon cancer, surpassing pathological and clinical risk factors. Prospective cohort studies also suggest there may be a predictive role for ctDNA on the decision for consideration of adjuvant therapy. Currently, randomized clinical trials are enrolling to better define this role. In this review article, we review recent literature on ctDNA and its role in patients with colon cancer. We also elaborate on the future clinical utility of ctDNA in clinical practice and the unmet need for research to optimize currently available ctDNA assays.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251317094"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study.","authors":"Bingqing Luo, Xiaoyan Tan, Yanfang Zhang, Xiao Hu, Hanqing Zeng, Hongbo Xiao, Shifeng Lou, Kang Zhou","doi":"10.1177/15330338241312436","DOIUrl":"10.1177/15330338241312436","url":null,"abstract":"<p><p>BackgroundEffective treatment options are limited for elderly patients with acute myeloid leukemia (AML). A prospective phase II study was conducted to investigate the safety and efficacy of pegylated liposomal doxorubicin (PLD) combined with low-dose cytarabine (LDAC) and granulocyte colony-stimulating factor (G-CSF) in newly diagnosed older and unfit AML patients.MethodsTwenty-two patients were enrolled and deemed evaluable. The study included one cycle of induction and four cycles of consolidation, followed by maintenance therapy.ResultsThe median age of enrolled patients was 71.5 years (range, 63 to 82 years), and 16 patients (72.7%) were over 70 years of age. The overall response rate (ORR) was 77.3% (n = 17) and the complete remission (CR)/complete remission with incomplete recovery (CRi) rate was 63.6% (n = 14) after the first induction cycle. With a median follow-up of 12.4 months, eight patients (57.1%) relapsed, with a median time to relapse of 12.3 months. The median duration of response (DOR) was 11.9 months (95% CI, 6.4 to NA months), the median overall survival (OS) was 15 months (95% CI, 8.4 to 21.6 months), and the median progression-free survival (PFS) was 7.5 months (95% CI, 4.6 to 15.1 months). Common grade 3 or greater adverse events included febrile neutropenia (77.8%) and infection (63.6%), with pneumonia being the most common (10, 45.5%). There was one death (4.5%) within 30 days.ConclusionThe combination of PLD, LDAC, and G-CSF is well-tolerated and exhibits high rates of CR/CRi and low early mortality, providing an attractive treatment option for newly diagnosed elderly and unfit AML patients.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241312436"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Retraction: Potential Molecular Mechanisms of AURKB in the Oncogenesis and Progression of Osteosarcoma Cells: A Label-Free Quantitative Proteomics Analysis.","authors":"","doi":"10.1177/15330338251321913","DOIUrl":"10.1177/15330338251321913","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251321913"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparative Dosimetry and Biological Risk Assessment of Lung Oligometastasis SBRT: VMAT, Helical Tomotherapy, and CyberKnife.","authors":"Zhenjiong Shen, Mingyuan Pan, Lan Sun, Aihui Feng, Yanhua Duan, Hengle Gu, Yan Shao, Hua Chen, Hao Wang, Ying Huang, Zhiyong Xu","doi":"10.1177/15330338251330781","DOIUrl":"10.1177/15330338251330781","url":null,"abstract":"<p><p>PurposeTo compare the dosimetry and biological risk of volumetric modulated arc therapy (VMAT), helical tomotherapy (HT) and cyberKnife (CK) in the treatment of lung oligometastases.Methods and materialsThis retrospective study included a cohort of 21 lung oligometastasis patients, each with 2 or 3 lesions, who had previously undergone stereotactic body radiation therapy (SBRT). VMAT, HT and CK plans were made for each patient. The dose distribution of planning target volume (PTV) and organs at risk (OARs) were evaluated. Three biological risks were evaluated, namely radiation pneumonitis (RP), coronary artery disease (CAD) and congestive heart failure (CHF). Monitor Units (MUs) and beam-on-time were also recorded.ResultsAll techniques were able to produce clinically deliverable plans. The expected biological risks for VMAT plans, CK plans, and HT plans were 6.69%, 5.05%, 5.88% for RP, 1.20%, 1.15%, and 1.17% for CAD, 1.26%, 1.19%, and 1.22% for CHF. The expected risks of RP were slightly lower in CK plans compared to VMAT and HT plans (p < 0.001), with VMAT plans showing the highest expected risks. For central lung cancer, the expected CAD risks of CK and HT plans were lower than those of VMAT plans (p < 0.05). The delivery efficiency of VMAT plans was significantly higher than that of CK plans and HT plans.ConclusionsAll three techniques, VMAT, HT, and CK, meet the therapeutic requirements for target coverage and dose constraints for OARs. Although there are statistical differences, the difference between the expected risk values of RP and CAD is very small, so the clinical manifestations may not show differences.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251330781"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hang Lu, Xin Yu, Zhiliang Xu, Jingwen Deng, Master Jingwen Zhang, Yimin Zhang, Shengrong Sun
{"title":"Prognostic Value of IGFBP6 in Breast Cancer: Focus on Glucometabolism","authors":"Hang Lu, Xin Yu, Zhiliang Xu, Jingwen Deng, Master Jingwen Zhang, Yimin Zhang, Shengrong Sun","doi":"10.1177/15330338241271998","DOIUrl":"https://doi.org/10.1177/15330338241271998","url":null,"abstract":"IGFBP6, a member of the IGF binding protein (IGFBP) family, is a specific inhibitor of insulin-like growth factor II (IGF-II) and can inhibit the growth of malignant tumors overexpressing IGF-II. Type 2 diabetes (T2D) is a basic disorder of glucose metabolism that can be regulated by IGF-related pathways. We performed bioinformatics analysis of the TCGA database to explore the possible mechanism of IGFBP6 in breast cancer (BC) metabolism and prognosis and collected clinical samples from BC patients with and without T2D to compare and verify the prognostic effect of IGFBP6. In our study, the levels of IGFBP1–6 were positively correlated with overall survival (OS) in patients with breast cancer. IGFBP6 was upregulated in estrogen receptor (ER)-positive BC, and ER-positive and progesterone receptor (PR) positive patients had a higher expression level of IGFBP6 than ER-negative and PR-negative patients. IGFBP6 could be used as an independent prognostic factor in BC. The expression of IGFBP6 was decreased in BC tissue, and BC tissue from patients with T2D had lower IGFBP6 expression levels than BC tissue from patients without T2D. IGFBP6 is mainly involved in the PI3K–Akt and TGF-β signaling pathways and tumor microenvironment regulation. In terms of metabolism, the expression of IGFBP6 was negatively correlated with that of most glucose metabolism-related genes. IGFBP6 expression was mainly correlated with mutations in TP53, PIK3CA, CDH1, and MAP3K1. In addition, the upregulation of IGFBP6 in BC increased the drug sensitivity to docetaxel, paclitaxel and gemcitabine. Overall, these results indicated that high expression of IGFBP6 is associated with a good prognosis in BC patients, especially in those without T2D. It is not only involved in the maintenance of the tumor microenvironment in BC but also inhibits the energy metabolism of cancer cells through glucose metabolism-related pathways. These findings may provide a new perspective on IGFBP6 as a potential prognostic marker for BC.","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"3 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142263447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}